Bulk Pharmaceutical API Sources for CROMOPTIC

Bulk Pharmaceutical API Sources for CROMOPTIC

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-002-509-361
Hangzhou APIChem Technology		AC-18734
Amadis Chemical		A809913
TimTec		ST50999688
AKos Consulting & Solutions		AKOS015895760
AKos Consulting & Solutions		AKOS015913923

Bulk Active Pharmaceutical Ingredient (API) Sources for: CROMOPTIC

Last updated: July 29, 2025

---

Introduction

Cromoptic, an ophthalmic antihistamine agent primarily used to alleviate allergic conjunctivitis, depends heavily on the reliable sourcing of its active pharmaceutical ingredient (API). In the pharmaceutical industry, ensuring consistent API quality, regulatory compliance, and supply chain robustness is critical for manufacturing efficacy and patient safety. This article explores the global landscape of Bulk API sources for Cromoptic, emphasizing key manufacturers, geographic distribution, quality standards, and supply chain considerations essential for pharmaceutical companies and formulators.

---

Overview of Cromoptic API

Cromoptic’s API is Olopatadine hydrochloride, a selective H1 antihistamine with mast cell stabilizer properties. Its synthesis involves complex chemical processes that demand high purity and strict adherence to Good Manufacturing Practices (GMP) [1]. The API supply chain is characterized by a diverse international network, encompassing large-scale manufacturers, contract manufacturing organizations (CMOs), and specialized chemical producers.

---

Global API Manufacturers for Olopatadine Hydrochloride

1. Major Regional Suppliers

• India: India remains the dominant source of Olopatadine hydrochloride API, with multiple pharmaceutical excipient and API manufacturers offering competitive pricing and large production capacities. Companies such as Mida Chemical Ltd., Hetero Labs Ltd., and Lanxi Huahao Pharmaceutical are notable players providing GMP-compliant APIs (referenced in [2]).

• China: Chinese API manufacturers have increased their production capacities, with companies like Shanghai Desano Pharmaceutical and Kunshan Sinomed Chemical offering Olopatadine API, often at lower costs. While regulatory standards vary, many Chinese entities adhere to international GMP standards, particularly for exports (see [3]).

• South Korea and Japan: These countries host premium API producers such as Samyang Pharm and MJN that prioritize higher purity levels, rigorous certification, and advanced quality management systems, albeit at a premium price point [4].

• Europe and North America: Fewer domestic producers exist due to manufacturing complexities and market decentralization. However, some European firms like Fresenius Kabi and North American contract manufacturers supply high-quality APIs under strict regulatory oversight for specialized formulations.

---

Key API Suppliers and Contract Manufacturers

• Fangda Pharmaceutical (China): Offers Olopatadine hydrochloride API synthesized with high purity, compliant with USFDA, EMA, and other international standards.

• Hetero Labs Ltd. (India): Recognized for large production capacity and GMP compliance, Hetero supplies APIs for ophthalmic applications globally.

• Hikma Pharmaceuticals (Jordan): Focuses on high-quality APIs for sterile ophthalmic formulations, with certifications favorable for regulated markets.

• Wuhan Sanyuan Bio-Technology (China): Provides competitive API pricing with proven quality records, especially aimed at emerging markets.

• Contract Manufacturers (CMOs): Companies like MacLeod Pharmaceuticals (India) and LGM Pharma act as intermediaries, sourcing APIs from various producers and conducting rigorous quality assurance processes for clients [5].

---

Supply Chain and Regulatory Considerations

Regulatory Compliance: Quality standards such as USP, EP, and JP are crucial benchmarks for Olopatadine hydrochloride APIs. Manufacturers must maintain cGMP compliance, with certifications from regulatory agencies like the USFDA, EMA, or equivalent authorities to facilitate international distribution.

Supply Chain Risks: The API supply chain faces challenges such as geopolitical tensions, raw material shortages, and logistical disruptions. Reliance on a limited number of producers heightens vulnerability; thus, diversification remains essential.

Quality Assurance and Due Diligence: Good practices include auditing suppliers, verifying certification statuses, and conducting batch-to-batch testing. These practices ensure API consistency, reducing regulatory risks associated with substandard ingredients.

---

Market Dynamics and Trends

• Growing Demand: The ophthalmic pharmaceutical market projected to grow at a CAGR of approximately 5% [6], increases the demand for Olopatadine API, driving investments in manufacturing capacities, particularly in India and China.

• Regulatory Stringency: Increasing strictness by agencies like the USFDA and EMA prompts OEMs to prioritize API sources with traceable quality standards, potentially limiting supplier options to those with recognized certifications.

• Sourcing Diversification: To mitigate supply chain risks, pharmaceutical companies increasingly seek multi-sourcing strategies, engaging both established and emerging API suppliers with proven compliance histories.

---

Emerging Opportunities

• Vertical Integration: Pharmaceutical firms are exploring vertical integration, including API manufacturing or acquisition of API production units, to secure supply and control quality.

• Regulatory Accelerators: Suppliers with expedited approval pathways for new batches or expedited certifications are gaining favor, especially amid global supply constraints.

• Innovation in Synthesis: Development of more sustainable, cost-effective synthetic routes is an area of active research, potentially broadening API source options in the future.

---

Summary of Key API Sourcing Strategies

Parameter	Considerations	Leading Suppliers	Implications
Quality Standards	Ensure cGMP compliance; verify certifications	Hetero Labs, Fangda Pharmaceutical	Risk mitigation; regulatory alignment
Geographic Diversity	Reduce dependency; balance cost vs. quality	India, China, South Korea	Supply chain resilience
Pricing Dynamics	Balance between cost and quality; negotiate volume discounts	Multiple Asian suppliers	Cost competitiveness
Regulatory Approval	Certification documentation; inspection readiness	Top-tier suppliers with USFDA/EMA approval	Easier market clearance
Supply Reliability	Track historical supply performance	Multi-source strategy	Minimize disruptions

---

Key Takeaways

• India and China dominate the Olopatadine hydrochloride API market, offering a broad base of suppliers capable of meeting global regulatory standards.

• Quality assurance is paramount, emphasizing compliance with cGMP, regular audits, and certification validation.

• Diversification of API sources remains essential to mitigate geopolitical, logistical, and regulatory risks.

• Regulatory trends favor suppliers with established approvals, which can streamline market entry and reduce approval timelines.

• Emerging synthetic methods and sustainability initiatives could reshape the API sourcing landscape over the coming years.

---

FAQs

Q1: What are the primary factors to consider when selecting an API supplier for Cromoptic?
A: Quality compliance (GMP certification, third-party audits), regulatory approvals, supply stability, price competitiveness, and geographic diversification.

Q2: Are Chinese API manufacturers reliable for ophthalmic APIs like Olopatadine hydrochloride?
A: Many Chinese manufacturers adhere to international GMP standards and hold approvals from agencies like the USFDA and EMA, making them suitable suppliers. Due diligence and certification verification are recommended.

Q3: How do regulatory requirements impact API sourcing for ophthalmic drugs?
A: Stringent regulatory standards necessitate sourcing from certified and compliant manufacturers to ensure product safety, facilitate approval processes, and maintain market access.

Q4: What are the risks associated with over-reliance on a single API supplier?
A: Supply disruptions, quality inconsistencies, regulatory non-compliance, and increased vulnerability to geopolitical or logistical issues.

Q5: How is the trend toward multi-sourcing influencing API procurement strategies?
A: It enhances supply chain resilience, provides price leverage, and reduces dependency, but adds complexity in quality management and regulatory oversight.

---

Conclusion

The sourcing landscape for Cromoptic’s API—Olopatadine hydrochloride—continues to evolve amidst growing demand, regulatory pressure, and geopolitical considerations. Indian and Chinese manufacturers stand out as primary sources, offering reliable and cost-effective options for global supply chains. Balancing quality, regulatory compliance, and diversification is vital for pharmaceutical companies aiming to ensure a resilient, compliant, and cost-efficient API procurement strategy.

---

References

[1] U.S. Pharmacopeia. Monograph on Olopatadine Hydrochloride.
[2] Indian Pharmaceutical Association. Market Trends in API Production.
[3] China National Pharmaceutical Industry Information Center. API Manufacturers Overview.
[4] Japanese Pharmacopoeia. Standards for Ophthalmic API Production.
[5] LGM Pharma. Contract API Manufacturing and Sourcing Recommendations.
[6] IQVIA. Global Ophthalmic Pharmaceuticals Market Report, 2022.